Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer by Markar, Sheraz R.

“…Utilisation of neoadjuvant therapy was associated with significant tumour downstaging as reflected by increases in pT0, pN0 and pTNM stage 0 disease, this effect was further enhanced with neoadjuvant chemoradiotherapy. …”
Get full text
Get full text
Get full text
Get full text

Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases by Chun, Yun Shin

“…PVE was performed in 18 group I and 12 group II patients without increase in morbidity. For group I, group II first stage, and group II second stage, respectively, morbidity (24%, 24%, 43%), median hospital stay (7 days, 6 days, 6.5 days) and 30 days postoperative mortality (2%, 0%, 0%) were not significantly different (P = NS). …”
Get full text
Get full text
Get full text

Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial by Eman Elmekaty (14777932)

“…Cox Hazard ratio for patients receiving pioglitazone was 1.10 (p=NS). A total of 4 patients died in the placebo group vs. 3 in the pioglitazone group (p =0.91). …”

A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle by Sanjay Kumar (8853)

“…By examining the effects of glycosylation and other structural-activity relationships, the presence of sugar moiety in flavonoids significantly reduces its binding energy. It increases the solubility of flavonoids leading to reduced toxicity and higher bioavailability. …”